Associations Between Greenspace and Cognitive Performance: James E. Galvin, MD, MPH
August 16th 2021The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the clinical significance of his findings on neighborhood tree canopy and brain health.
The State of the Alzheimer Disease Pipeline: Eric Reiman, MD
August 6th 2021The executive director of Banner Alzheimer’s Institute commented on ongoing research into amyloid plaque-reducing antibody therapies, the approval of aducanumab, and other initiatives with the ability to impact the treatment of Alzheimer disease.
Aducanumab Phase 4 Real-World Observational Study Announced
July 29th 2021The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.
Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy
July 28th 2021Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).